Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
Human epidermal growth factor (HER) 2 positivity and its association with clinicopathological factors remain unclear in Japanese gastric cancer (GC) patients. We performed a prospective, multicenter, observational cohort study to evaluate HER2 protein expression and gene amplification in Japanese metastatic and recurrent GC patients, and explored its correlations with clinicopathological features.
Methods
HER2 protein expression and gene amplification were centrally assessed in formalin-fixed, paraffin-embedded GC tissue by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Patient information was collected, and associations between clinicopathological factors and HER2 positivity (IHC score 3+ and/or FISH positive) and low HER2 expression (IHC score 0/FISH positive or IHC score 1+/FISH positive) were examined.
Results
From September 2011 to June 2012, 1461 patients were registered across 157 sites, and the HER2 status of 1427 patients was evaluated. The rate of HER2 positivity was 21.2 %, whereas the rate of high HER2 expression (IHC score 2+/FISH positive or IHC score 3+) was 15.6 % and that of low HER2 expression was 7.0 %. Multiple logistic regression analysis identified intestinal type, absence of peritoneal metastasis, and hepatic metastasis as significant independent factors related to HER2 positivity. The intestinal type was confirmed to be the GC subtype predominantly associated with lower HER2 expression. Sampling conditions including number of biopsy samples, formalin concentration, and formalin-fixation time did not significantly affect HER2 positivity.
Conclusions
HER2 expression in Japanese patients was comparable to that in other populations examined. Intestinal type was an independent factor related to HER2 positivity and low HER2 expression.
Trastuzumab (Herceptin) is a monoclonal antibody that specifically targets human epidermal growth factor receptor 2 (HER2), a receptor associated with gastric cancer (GC) tumorigenesis, by directly binding its extracellular domain [1]. The Trastuzumab for GAstric Cancer (ToGA) study, an open-label, international, multicenter, phase III, randomized controlled trial, examined the clinical efficacy and safety of trastuzumab combined with standard chemotherapy (capecitabine or intravenously administered 5-fluorouracil and cisplatin) for first-line treatment of HER2-overexpressing advanced gastric or gastroesophageal junction cancers. Addition of trastuzumab therapy to chemotherapy improved median survival (13.8 months) compared with chemotherapy alone (11.1 months) (P = 0.0046), and showed significant improvements in time to progression and progression-free survival in the trastuzumab-treated group, with a comparable toxicity profile [2]. As a result, trastuzumab therapy plus chemotherapy has become the standard treatment for HER2-positive advanced GC patients, as determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). In Japan and the USA, trastuzumab is approved for patients with metastatic GC whose tumors are HER2 positive, as defined by a positive FISH result or an IHC score of 3+. In the European Union, however, trastuzumab is recommended only for individuals whose tumors have high HER2 protein expression, as defined by an IHC score of 2+/positive FISH result or an IHC score of 3+ based on the subset analysis of the ToGA study. HER2 evaluation has therefore become an important approach for predicting clinical efficacy of trastuzumab. The variation in the HER2-positivity rate between countries possibly reflects the unstandardized testing modality and other country-specific factors; it was identified as 27 % in Japanese patients in the ToGA study [3, 4], which was higher than that identified in previous studies in Japan [5‐7].
In the ToGA study, the strong effect of trastuzumab was evident in patients with higher HER2 protein expression (IHC score 2+/FISH positive or IHC score 3+), whereas the efficacy was unclear in patients with low HER2 expression (IHC score 0/FISH positive or IHC score 1+/FISH positive). These results were obtained via a subgroup analysis, and may be affected by the smaller number of patients with low HER2 expression than higher HER2 protein expression. Thus, it is premature to conclude that addition of trastuzumab therapy to chemotherapy is not beneficial in patients with low HER2 expression. Additionally, little has been reported about the clinicopathological features of patients with low HER2 expression [8‐10].
Anzeige
In unresectable cases, tumor behavior before treatment is evaluated by biopsy specimens. However, because GC is considered a mixture of heterogeneous tumor types, small biopsy specimens may not reflect its overall behavior, and few studies have focused on HER2-positivity concordance between diagnostic biopsy specimens and surgical specimens [11, 12]. Because of tumor heterogeneity, the accuracy of HER2 testing can be affected by the site of the examined HER2-stained cells; thus, gastric biopsies could yield false-negative results [13].
We performed a prospective, multicenter, observational cohort study (JFMC44-1101) to evaluate HER2 expression and gene amplification in consecutively registered Japanese patients with metastatic (excluding curatively resected cases) or recurrent GC, and explored the clinicopathological features in relation to HER2 positivity (IHC score 3+ and/or FISH positive) or low HER2 expression (IHC score 0/FISH positive or IHC score 1+/FISH positive). Furthermore, we evaluated the relationship between HER2 protein expression/gene amplification and sampling conditions to ascertain whether HER2 positivity in GC patients can be accurately determined from routinely prepared formalin-fixed, paraffin-embedded tissues.
Methods
Patients
JFMC44-1101 is a multicenter, observational cohort study to evaluate HER2 protein expression and gene amplification in consecutively registered Japanese patients with metastatic (excluding curatively resected cases) or recurrent GC. This trial was approved by the central ethics committee of the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) and the institutional review boards of all participating centers. In total, 1427 cases of GC were studied, of which 396 cases were proximal and 1031 were distal. Patients were classified into two groups on the basis of age (younger than 65 years or 65 years or older), according to the WHO classification [14]. All patients provided written informed consent before undergoing study-specific screening procedures. The trial was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN ID UMIN000006190). Patient information was collected on the basis of the Japanese Classification of Gastric Carcinoma (third English edition) [15].
Selection criteria
Eligible patients were aged 20 years or older with histologically confirmed adenocarcinoma and in whom metastatic or recurrent GC had been diagnosed after August 2011. Additional eligibility criteria included available pathological tissue samples (six 4-μm-thick tissue sections), and written informed patient consent and consent to disseminate the clinical data.
Anzeige
HER2 evaluation
Excised tissue was formalin fixed and paraffin embedded by conventional histological methods. Six 3–5-µm sections were submitted per paraffin-embedded tissue block to allow assessment of the HER2 status: one section was used for each of hematoxylin and eosin staining, IHC, IHC negative control, and FISH, and the remaining two sections were retained as backup specimens. HER2 evaluation was performed centrally with an in vitro diagnosis kit validated by the Japanese Ministry of Health, Labour and Welfare, according to the manufacturer’s procedure as follows: tissue sections were tested for HER2 status by IHC with the PATHWAY anti-HER2 (4B5) rabbit monoclonal primary antibody (Roche Diagnostics, Tokyo, Japan), and by FISH with a PathVysion HER-2 DNA probe kit (Abbott Japan, Tokyo, Japan). IHC and FISH results were interpreted centrally, and HER2 positivity was defined as an IHC score of 3+ and/or a positive FISH result in accordance with the ToGA study parameters [2]. High HER2 expression was defined as an IHC score of 2+/positive FISH result or an IHC score of 3+, and low HER2 expression was defined as an IHC score of 0/positive FISH result or an IHC score of 1+/positive FISH result. The IHC scoring criteria were as follows: IHC score 0, no staining or membrane staining in less than 10 % of invasive tumor cells; IHC score 1+, weak membrane staining in 10 % or more of invasive tumor cells; IHC score 2+, weak to moderate complete or basolateral membrane staining in 10 % or more of invasive tumor cells; and IHC score 3+, moderate to strong complete or basolateral membrane staining in 10 % or more of invasive tumor cells. To determine FISH-positive status, we determined the fluorescence signal ratio of HER2 (orange) to chromosome enumeration probe 17 (CEP17; green) by counting 20 cancer cells under a fluorescence microscope with a ×100 objective lens. A sample was considered negative for gene amplification (FISH negative) if the HER2-to-CEP17 ratio was less than 2.0, and positive for gene amplification (FISH positive) if the ratio was 2.0 or greater. A HER2-to-CEP17 ratio of 1.8–2.2 (inclusive) was considered equivocal, and was found in 40 cancer cells. Samples were evaluated with a conventional histopathology method, and associations between clinicopathological factors and HER2 positivity or low HER2 expression were examined.
Statistical analysis
Data were analyzed with the Statistical Package for SAS version 9.2 (SAS Institute, Cary, NC, USA). Fisher’s test, Wilcoxon’s test, and the chi-squared test were used to test the association between HER2 status and clinicopathological characteristics. To assess the association of HER2 status with clinicopathological features, univariate and multivariate logistic regression analyses were performed. Confidence intervals were computed with the normal approximation of the binomial distribution.
Results
Patient and sample characteristics
The trial profile is summarized in Fig. 1. A total of 1461 patients from 157 sites were registered between September 2011 and June 2012. Of these, the HER2 status of 1427 patients was evaluated by both IHC and FISH. Samples were collected from the major tumor site in each patient and were categorized as proximal if they were located in the upper third of the stomach or in the esophagus, and distal if they were situated in the middle third or lower third of the stomach; 27.8 % (396/1427) were proximal GCs and 72.2 % (1031/1427) were distal GCs. Patient and sample characteristics at the baseline are summarized in Table 1. The median age of the patients was 68 years (range 23–99 years). The correlations between patient or sample characteristics and HER2 status are summarized in Table 2. Histopathological groupings based on the Lauren classification revealed that 642 patients had intestinal-type tumors and 770 had diffuse-type tumors. Samples were obtained via surgical excision (678 patients) or biopsy (749 patients), and sample collection sites consisted of primary tumors (1348 patients) or metastatic regions (79 patients). HER2-positivity rates in surgically resected tumors and biopsy specimens were significantly different at 18.4 and 23.6 % (Fisher’s test, P = 0.016), respectively (Table 2). In univariate analysis, the factor biopsy specimen was found to be significantly associated with HER2 positivity (Fig. 2a). However, this association was lost in the multivariate analysis (Fig. 2b).
Fig. 1
Trial profile. Human epidermal growth factor receptor 2 (HER2) evaluation by immunohistochemistry and fluorescence in situ hybridization (FISH) in 1427 samples
Table 1
Characteristics of gastric cancer (GC) patients (n = 1427)
Recurrent GC
Metastatic GC
Primary tumor resection
Primary tumor no resection
n = 376
n = 318
n = 733
Sex
Male
276 (73.4 %)
215 (67.6 %)
529 (72.2)
Female
100 (26.6 %)
103 (32.4 %)
204 (27.8)
Age
Median (years)
68
Range (years)
23–99
<65 years
158 (42.0 %)
108 (34.0 %)
273 (37.2 %)
≥65 years
218 (58.0 %)
210 (66.0 %)
460 (62.8 %)
PS (ECOG)
0
242 (64.4 %)
180 (56.6 %)
438 (59.8 %)
1, 2, 3, 4
134 (35.6 %)
138 (43.4 %)
295 (40.2 %)
Source of sample
Biopsy
29 (7.7 %)
22 (6.9 %)
698 (95.2 %)
Surgical excision
347 (92.3 %)
296 (93.1 %)
35 (4.8 %)
Depth of tumor invasion
T1a
4 (1.1 %)
0
1 (0.1 %)
T1b
19 (5.1 %)
4 (1.3 %)
4 (0.5 %)
T2
45 (12.0 %)
11 (3.5 %)
20 (2.7 %)
T3
121 (32.2 %)
36 (11.3 %)
142 (19.4 %)
T4a
153 (40.7 %)
200 (62.9 %)
367 (50.1 %)
T4b
33 (8.8 %)
63 (19.8 %)
160 (21.8 %)
Tx
0
4 (1.3 %)
39 (5.3 %)
Unclear
1 (0.3 %)
Lymph node metastasis
N0
65 (17.3 %)
22 (6.9 %)
93 (12.7 %)
N1
57 (15.2 %)
39 (12.3 %)
44 (6.0 %)
N2
76 (20.2 %)
43 (13.5 %)
108 (14.7 %)
N3a
106 (28.2 %)
75 (23.6 %)
83 (11.3 %)
N3b
61 (16.2 %)
102 (32.1 %)
25 (3.4 %)
NX
11 (2.9 %)
37 (11.6 %)
380 (51.8 %)
Peritoneal metastasis
P0
358 (95.2 %)
159 (50.0 %)
192 (26.2 %)
P1
10 (2.7 %)
151 (47.5 %)
333 (45.4 %)
Unclear
8 (2.1 %)
8 (2.5)
208 (28.4 %)
Peritoneal lavage cytology
CY0
316 (84.0 %)
115 (36.2 %)
85 (11.6 %)
CY1
0
159 (50.0 %)
161 (22.0 %)
Unclear
60 (16.0 %)
44 (13.8 %)
487 (66.4 %)
Hepatic metastasis
H0
371 (98.7 %)
257 (80.8 %)
493 (67.3 %)
H1
3 (0.8 %)
57 (17.9 %)
209 (28.5 %)
Unclear
2 (0.5 %)
4 (1.3 %)
31 (4.2 %)
ECOG Eastern Cooperative Oncology Group, PS performance status
Table 2
Correlation between patient and sample characteristics and human epidermal growth factor receptor 2 (HER2) status (n = 1427)
Number
HER2 positivity (%)
HER2 positive (n = 302)
HER2 negative (n = 1125)
Diagnosis status
Metastatic
1051
22.2
233
818
Recurrent
376
18.4
69
307
Time to recurrence
<18 months
212
20.3
43
169
≥18 months
164
15.9
26
138
Sex
Male
1020
23.7
242
778
Female
407
14.7
60
347
Age
<65 years
539
18.7
101
438
≥65 years
888
22.6
201
687
Tumor location: three gastric regions (major site)
U
391
21.2
83
308
M
548
19.9
109
439
L
480
22.3
107
373
Other (E or D)
6
33.3
2
4
Tumor location: cross-sectional part (major site)
Less
550
22.0
121
429
Gre
202
23.8
48
154
Ant
142
21.8
31
111
Post
188
20.2
38
150
Circ
332
18.1
60
272
Macroscopic type
Type 0
46
28.3
13
33
Type 1
40
30.0
12
28
Type 2
291
26.5
77
214
Type 3
639
23.6
151
488
Type 4
353
11.3
40
313
Type 5
55
14.5
8
47
Histological classificationa
pap
38
36.8
14
24
tub1
155
38.1
59
96
tub2
353
33.1
117
236
por1
359
19.8
71
288
por2
347
7.8
27
320
sig
134
6.7
9
125
muc
41
12.2
5
36
Lauren classificationb
Intestinal
642
32.7
210
432
Diffuse
770
11.7
90
680
Peritoneal metastasis
P0
709
23.1
164
545
P1
494
14.2
70
424
Peritoneal lavage cytology
CY0
516
18.6
96
420
CY1
320
15.9
51
269
Hepatic metastasis
H0
1121
18.0
202
919
H1
269
34.9
94
175
Distant metastasisc
dM0
934
18.0
168
766
dM1
446
28.0
125
321
Lymph node metastasis
N0
180
12.8
23
157
N1
140
23.6
33
107
N2
227
21.6
49
178
N3a
264
24.6
65
199
N3b
188
13.8
26
162
Depth of tumor invasion
T1
32
37.5
12
20
T2
76
25.0
19
57
T3
299
28.4
85
214
T4a
720
16.5
119
601
T4b
256
21.5
55
201
Source of sample
Surgical excision
678
18.4
125
553
Biopsy
749
23.6
177
572
No. of biopsy samples
1–3
339
23.0
78
261
4–8
378
24.1
91
287
≥9
31
25.8
8
23
Formalin concentration
10 %
950
20.7
197
753
15 %
129
16.3
21
108
20 %
335
25.1
84
251
>20 %
6
0.0
0
6
Formalin fixation time
<18 h
497
22.9
114
383
≥18 h, <24 h
462
21.2
98
364
≥24 h, <48 h
269
17.5
47
222
≥48 h
186
22.6
42
144
Sample collection sites
Primary tumor
1348
21.7
292
1056
Metastatic region
79
12.7
10
69
Ant anterior wall, Circ circumferential, D duodenum, E esophagus, Gre greater curvature, L lower third, Less lesser curvature, M middle third, muc mucinous adenocarcinoma, pap papillary adenocarcinoma, por1 solid-type poorly differentiated adenocarcinoma, por2 non-solid-type poorly differentiated adenocarcinoma, Post posterior wall, U upper third, sig signet ring cell carcinoma, tub1 well-differentiated tubular adenocarcinoma, tub2 moderately differentiated tubular adenocarcinoma
aHistological features were classified on the basis of the Japanese Classification of Gastric Carcinoma (third English edition)
bFor Lauren classification, pap, tub, and por1 of type 1 or type 2 were defined as intestinal type, and the others were defined as diffuse type
cDistant metastasis was defined as metastasis to other organs excluding that detected in the peritoneum, by peritoneal lavage cytology, and in the liver
Fig. 2
Correlation of human epidermal growth factor receptor 2 (HER2) positivity with clinicopathological factors. a Univariate analysis of HER2 positivity (immunohistochemistry score 3+ and/or fluorescence in situ hybridization positive) in samples from gastric cancer (GC) patients. b Multivariate analysis of HER2-positivity in samples from GC patients (n = 1088). Red squares indicate a significant association with HER2 status (HER2 positive/negative). All P values are two-sided, with P < 0.05 indicating statistical significance. CI confidence interval, CY peritoneal lavage cytology, dM distant metastasis excluding that detected in the peritoneum, by peritoneal lavage cytology, and in the liver, H hepatic metastasis, N lymph node metastasis, P peritoneal metastasis, PS performance status, T depth of tumor invasion (color figure online)
×
×
HER2 positivity and correlation with clinicopathological factors
The overall HER2-positivity rate (IHC score 3+ and/or FISH positive) was 21.2 % [95 % confidence interval (CI) 19.1–23.4; 302 of 1427 patients]. There was no significant difference (P = 0.885; Fisher’s exact test, two-sided) in HER2 positivity between proximal GC cases (21.5 %; 85 of 396 cases) and distal GC cases (21.0 %; 217 of 1031 cases). The incidence of high HER2 protein expression (IHC score 3+ or IHC score 2+ and FISH positive) was 15.6 % (223 of 1427 patients). FISH was positive in 47.3 % of IHC score 2+ cases (61 of 129 patients) and 97.5 % of IHC score 3+ cases (158 of 162 patients) (Table 3). In the univariate analysis, HER2 positivity was significantly correlated with sex, histological type, peritoneal metastasis, hepatic metastasis, distant metastasis excluding that detected in the peritoneum, by peritoneal lavage cytology, and in the liver, depth of tumor invasion, macroscopic type, primary tumor location, size, and sample source (Fig. 2a). Multivariate logistic regression analysis revealed that intestinal type, absence of peritoneal metastasis, and hepatic metastasis were independent factors related to HER2 positivity (Fig. 2b). Sampling conditions such as number of biopsy samples, formalin concentration, formalin-fixation time, and sample source had no significant effect on HER2 positivity.
Table 3
Human epidermal growth factor receptor 2 positive rates as assessed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC)
FISH result
IHC score
Total
0
1+
2+
3+
Negative
573 (96.8 %)
484 (89.0 %)
68 (52.7 %)
4 (2.5 %)
1129 (79.1 %)
Positive
19 (3.2 %)
60 (11.0 %)
61 (47.3 %)
158 (97.5 %)
298 (20.9 %)
Total
592 (100 %)
544 (100 %)
129 (100 %)
162 (100 %)
1427 (100 %)
Correlation of HER2 gene amplification by FISH with clinicopathological factors in IHC score 0/1+ cases
The incidence of low HER2 expression (IHC score 0/FISH positive or IHC score 1+/FISH positive) was 7.0 % (79 of 1136 patients); of these patients, 3.2 % of IHC score 0 cases (19 of 592 patients) and 11 % of IHC score 1+ cases (60 of 544 patients) were FISH positive (Table 3). In the univariate analysis, low HER2 expression was significantly correlated with sex, histological type, peritoneal metastasis, hepatic metastasis, depth of tumor invasion, and primary tumor location (Fig. 3a). Finally, multivariate logistic regression analysis revealed that age (65 years or older), intestinal type, and T1–T3 stage were independent factors related to low HER2 expression (Fig. 3b). We performed ad hoc analysis in the surgical specimen group. In the univariate analysis (n = 569), low HER2 expression was significantly correlated with sex (odds ratio 0.409, 95 % CI 0.178–0.940, P = 0.035), histological type (odds ratio 0.257, 95 % CI 0.131–0.507, P < 0.001), hepatic metastasis (odds ratio 4.598, 95 % CI 2.013–10.505, P < 0.001), depth of tumor invasion (odds ratio 0.405, 95 % CI 0.215–0.763, P = 0.005), and formalin concentration (odds ratio 1.949, 95 % CI 1.035–3.669, P = 0.039). However, multivariate logistic regression analysis revealed that there were no independent factors related to low HER2 expression in the 392 of 569 patients for whom data were available.
Fig. 3
Correlation of human epidermal growth factor receptor 2 (HER2) gene amplification assessed by fluorescence in situ hybridization (FISH) with clinicopathological factors in immunohistochemistry (IHC) score 0/1+ cases. a Univariate analysis of low HER2 expression as assessed by IHC score 0/FISH-positive or IHC score 1+/FISH-positive samples from gastric cancer patients. b Multivariate analysis of low HER2 expression as assessed by IHC score 0/FISH-positive or IHC score 1+/FISH-positive samples from gastric cancer patients (n = 874). Red squares indicate a significant association with HER2 status (IHC score 0/FISH positive or IHC score 1+/FISH positive). All P values are two-sided, with P < 0.05 indicating statistical significance. CI confidence interval, CY peritoneal lavage cytology, dM distant metastasis excluding that detected in the peritoneum, by peritoneal lavage cytology, and in the liver, H hepatic metastasis, N lymph node metastasis, P peritoneal metastasis, PS performance status, T depth of tumor invasion (color figure online)
×
Discussion
Previous studies reported that the rate of HER2 positivity (IHC score 3+ and/or FISH positive) in Japanese GC patients was approximately 10–20 % [5‐7], but testing methods and interpretation criteria were not standardized. In this study, HER2 status was centrally assessed with a standardized method, which was used to prospectively interpret both the IHC data and the FISH data of the ToGA study; The rate of HER2 positivity was 21.2 % in Japanese patients, identical to the ToGA screening population [3]. The rate of HER2 positivity was reported as 27 % in Japanese patients in the ToGA study [4], higher than previously reported rates. This might be a result of bias toward patient selection from past reports [16‐18], because the primary purpose of the ToGA study was to assess the clinical efficacy and safety of trastuzumab rather than to evaluate HER2 positivity. The incidence of higher HER2 protein expression (IHC score 2+/FISH positive or IHC score 3+; 15.6 %) and the proportions of FISH positivity in IHC score 0 and IHC score 1+ cases (3.2 and 11 %) were comparable with those reported in the ToGA study [3]. Similarly, the concordance between IHC and FISH in our results is consistent with that reported in the ToGA study.
A high correlation between HER2 positivity and histological subtype was reported by several authors [19‐24]. In the ToGA study, HER2 positivity varied significantly according to histological subtype (intestinal type 31.8 %; diffuse type 6.1 %; mixed type 20 %) [3]; thus, intestinal type was strongly correlated with HER2 expression. Several reports indicated that intestinal type is associated with hematogenous metastasis, particularly to the liver [25], and with older age [26], whereas the diffuse type is adversely related to peritoneal dissemination [27]. In the present study, intestinal type, absence of peritoneal metastasis, and hepatic metastasis were shown to be independent factors related to HER2 positivity in a multivariate logistic regression analysis. This agrees with what is known about the histological type, i.e., intestinal or diffuse, and the association with accompanying hepatic or peritoneal metastasis, respectively.
Moreover, intestinal type, age (65 years or older), and T1–T3 stage were independent factors related to low HER2 expression (IHC score 0/1+ and FISH positive). This result reveals that HER2-related factors are associated with intestinal-type GCs. Diffuse-type GCs are more malignant than their intestinal-type counterparts, demonstrating early invasion into the muscularis propria [25]. A previous report demonstrated that diffuse-type advanced GC was significantly associated with advanced pathological T stage [28]. Thus, diffuse type is commoner in T4 tumors, whereas intestinal type is commoner in T1–T3 tumors. As intestinal type is the most robust factor related to HER2 expression, T1–T3 stage may be an independent factor related to low HER2 expression even in intestinal-type IHC score 0/1+ GC cases. However, the current study was limited by the extent and accuracy of the T staging, which was determined by either pathological or clinical diagnosis methods. To resolve these limitations, we performed ad hoc analyses for low HER2 expression (IHC score 0/FISH positive or IHC score 1+/FISH positive) in the surgical specimen group, because the T stage in the surgical samples was accurately determined pathologically. T1–T3 stage was statistically significantly correlated with low HER2 expression in the univariate analysis, but was not significantly correlated in the multivariate analysis. Likewise, intestinal type, sex, hepatic metastasis, and formalin concentration were statistically significantly associated with low HER2 expression in the univariate analysis; however, there were no significant differences in the multivariate analysis. The discrepancies in these analyses may result from the multivariate analysis being performed only in 392 of 569 cases owing to missing data in the remaining cases, thereby conferring a lack of statistical significance. Further studies are required to confirm this result, and considering these limitations, we cannot conclude that depth of tumor invasion is a factor related to low HER2 expression.
Anzeige
There are several factors that are reported to affect HER2 staining results, such as type of fixative, total fixation time, fixative pH, tissue type, and time before fixation. In the present study, we evaluated the relationship between HER2 expression and sampling conditions; however, the number of biopsy samples, formalin concentration, and formalin-fixation time had no significant effect on HER2 positivity and low HER2 expression. Unfortunately, the recommended conditions for fixation could not be adhered to in this study because the biopsy specimens and surgically resected specimens were mixed up and because correlations between formalin concentration and fixation time could not be undertaken. Moreover, the time before fixation (so-called cold ischemia) and the specimen size were unclear. Further prospective studies aiming to comprehensively evaluate the effects of formalin concentration, formalin-fixation time, and cold ischemia on HER2 testing are required.
There was concern that examination of gastric biopsy samples alone might introduce false-positive and/or false-negative data, because HER2 intratumoral heterogeneity in GC is observed in 20–70 % of HER2-positive tumors [13, 29] and is the major cause of discrepancies between biopsy samples and surgical specimens. In the multivariate analysis of the present study results, HER2-positivity rates in surgically resected tumors and biopsy samples were not significantly different, similar to the findings in the HER-EAGLE study [24]. However, these studies were limited in that the correlation between surgical specimens and biopsy samples was not paired, although this contrasts with the GERCOR study, where the overall concordance rate between surgical specimens and paired biopsy samples reached 94 % [12]. We also examined the concordance between predominant histological type and histological type with a HER2-positive component, which was determined as 81.3 % with the Lauren classification (data not shown). Approximately 20 % of cases showed a discrepancy; therefore, gastroenterologists should consider performing multiple biopsy sampling from varied collection sites to overcome tumor heterogeneity in GC.
In conclusion, HER2 expression in a Japanese GC population was similar in distribution to that identified in the ToGA study. Intestinal type was revealed as an independent factor related to both HER2 positivity and low HER2 expression.
Acknowledgments
This trial was supported by the Japanese Foundation for Multidisciplinary Treatment of Cancer. Editorial support was provided by H. Nikki March and was funded by Chugai Pharmaceutical Co. Ltd.
Anzeige
Conflict of interest
S. Matsusaka has received commercial research grants from Taiho Pharmaceutical Co. Ltd. K. Nishikawa has received commercial research grants and personal fees from Yakult Honsha Co. Ltd, Taiho Pharmaceutical Co. Ltd, and Ajinomoto Pharmaceuticals, and personal fees from Chugai Pharmaceutical Co. Ltd. Tsumura Co. Ltd, and Terumo Corporation. T. Yoshikawa received commercial research grants and personal fees from Chugai Pharmaceutical Co. Ltd during the conduct of the study, has received grants and personal fees from Taiho Pharmaceutical Co. Ltd, Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd, Yakult Honsha Co. Ltd, Covidien Japan Co. Ltd, and the nonprofit organization Kanagawa Standard Anti-cancer Therapy Support System, has received personal fees from Eli Lilly Japan K.K., Abbott Japan Co. Ltd, Kaken Pharmaceutical Co. Ltd, Johnson & Johnson K.K., Takeda Pharmaceutical Co. Ltd, Secom Medical System Co. Ltd, Nikkei Business Publications, and the nonprofit organizations Tokyo Cooperative Oncology Group, Clinical Training Support Council, and Cancer Net Japan, and has received grants from Daiichi Sankyo Co. Ltd and Nippon Kayaku Co. Ltd. A. Ochiai has received commercial research grants from Bayer Ltd, Ventana Medical Systems Inc., Eli Lilly Japan K.K., Toray Industries Inc., Takeda Pharmaceutical Co. Ltd, Taiho Pharmaceutical Co. Ltd, Merck Serono Co. Ltd, Janssen Pharmaceutical K.K., Eisai Co. Ltd, Otsuka Pharmaceutical Co. Ltd, and Daiichi Sankyo Co. Ltd, and nonfinancial support from Fujifilm Co. Ltd. S. Morita has received commercial research grants and personal fees from Chugai Pharmaceutical Co. Ltd. T. Sano has received personal fees from Taiho Pharmaceutical Co. Ltd, Sanofi K.K., Yakult Honsha Co. Ltd, and Chugai Pharmaceutical Co. Ltd. Y. Kodera has received commercial research grants and personal fees from Chugai Pharmaceutical Co. Ltd, grants and personal fees from Taiho Pharmaceutical Co. Ltd, Sanofi K.K., Bristol-Myers Squib Ltd, Merck Serono Co. Ltd, Yakult Honsha Co. Ltd, Daiichi Sankyo Co. Ltd, Otsuka Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, Johnson & Johnson K.K., Asahi Kasei Pharma Corporation, Shionogi & Co. Ltd, Eli Lilly Japan K.K., Pfizer Japan Inc., Ajinomoto Pharmaceuticals, Ono Pharmaceutical Co. Ltd, Kaken Pharmaceutical Co. Ltd, Covidien Japan Co. Ltd, Tsumura Co. Ltd, and grants from Eisai Co. Ltd, Abbott Japan Co. Ltd, CSL Behring Ltd, Teijin Pharma Ltd, the Japan Blood Products Organization, Torii Pharmaceutical Co. Ltd, and Mitsubishi Tanabe Pharma Corporation. Y. Kakeji has received personal fees from Chugai Pharmaceutical Co. Ltd. J. Sakamoto has received personal fees from Takeda Pharmaceutical Co. Ltd and Tsumura Co. Ltd. K. Yoshida received commercial research grants from Chugai Pharmaceutical Co. Ltd during the conduct of the study, has received grants and personal fees from Taiho Pharmaceutical Co. Ltd, Pfizer Japan Inc., Chugai Pharmaceutical Co. Ltd, Yakult Honsha Co. Ltd, Bristol-Myers Squibb Ltd, and Kyowa Hakko Kirin Co. Ltd, honoraria from Taiho Pharmaceutical Co. Ltd, Pfizer Japan Inc., Chugai Pharmaceutical Co. Ltd, Kyowa Hakko Kirin Co. Ltd, and Yakult Honsha Co. Ltd, and has acted as a consultant or advisor for Taiho Pharmaceutical Co. Ltd and F. Hoffmann-La Roche Ltd. All remaining authors declare that they have no conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.
Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.
Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.
Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.
Update Chirurgie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
